Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Classical hematology 3Genitourinary 1

Conditions

Anemia 3Neoplasms 2Renal Insufficiency, Chronic 1Kidney Failure, Chronic 1

Interventions

Epoetin Alfa 55Darbepoetin alfa 39epoetin beta 14ferric carboxymaltose 11Lenalidomide 5Cyclophosphamide 5luspatercept 4fludarabine phosphate 4fludarabine 4Erythropoietin 4Cyclosporine 4Cisplatin 4Busulfan 4Blood Transfusion 4Biopsy 4ACE-011 4peginesatide 3iron isomaltoside 1000 3hematide 3ferrous sulfate 3ferric gluconate 3Radiotherapy 3Iron-Dextran Complex 3Filgrastim 3Ferric Oxide, Saccharated 3Erythrocyte Transfusion 3Antilymphocyte Serum 3thymoglobulin 2telapristone acetate 2ruxolitinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Anemia × peginesatide × Clear all
NCT00097747 2012-12-21

Safety and Pharmacokinetics of Single Intravenous Doses of Peginesatide in Healthy Volunteers

Affymax

Phase 1 Completed
28 enrolled
Classical hematologyGenitourinary

Anemia, Kidney Failure, Chronic, Neoplasms, Renal Insufficiency, Chronic

NCT00272662 2012-12-21

Study of Subcutaneously Administered Peginesatide in Anemic Cancer Patients Receiving Chemotherapy

Affymax

Phase 2 Completed
60 enrolled
Classical hematology

Anemia, Neoplasms

NCT00629876 2011-12-01

A Safety and Tolerability Study of Peginesatide in Anemic Cancer Patients Receiving Cytotoxic Chemotherapy.

Takeda

Phase 1 Terminated
2 enrolled
Classical hematology

Anemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡